GSK to acquire Canadian biopharma company BELLUS Health for $2bn
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its specialty medicines and respiratory pipeline. The deal gives GSK access to a late-stage P2X3 antagonist called camlipixant, which is intended for the treatment of refractory chronic cough (RCC). Presently, camlipixant […]